Coherus Oncology, Inc.CHRSNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank38
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P38
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$-138.51M-577.7%
2024$-20.44M+88.3%
2023$-175.17M+28.0%
2022$-243.16M-528.0%
2021$-38.72M-126.4%
2020$146.91M+850.4%
2019$15.46M+109.7%
2018$-160.06M+21.9%
2017$-204.86M+20.9%
2016$-259.06M-